Wednesday, 31 July 2019

Needles Market Growth And Future Outlook By 2025

Needles Market – Advancing Technology for Painless Future

Needles are used for injecting medications or for drawing blood from the body. It has three parts, which includes a long shaft, slanted tip called bevel, and hub which fits in the tip of the syringe. Different types of needles are routinely used in clinical practice for variety of applications such as administering medicine within various layers of skin, anesthetic procedure, and different surgical procedures. Needles are available in different types and different materials depending upon the need of the clinician. Conventional needles are used for general purpose medicine administration, fill and filter needles are used for vaccination and other sterile products, safety needles are used for blood collection and medicine administration in cases in which chances of contamination from infectious disease high. It also depends on its application area, for instance pen needles are used by diabetes patients for injecting daily dose of insulin, blood collection needle are used for diagnostic purposes, and suture needles are used for surgical purposes.


The needles market was valued at US$ 5.75 billion in 2017 and is expected to witness a robust CAGR of 7.6% over the forecast period (2017–2025).

High prevalence of chronic diseases worldwide is projected to fuel growth of the needles market

Several factors are associated with increasing adoption of needles worldwide. One of the major factors is high prevalence of chronic disease across the world, which is propelling demand for needles. According to the World Health Organization (WHO), in 2017, non-communicable diseases such as cancer, diabetes, cardiovascular diseases, and lung diseases accounted for around 70% death worldwide, which was majorly from middle and low income economies. Furthermore, chronic diseases are expected to account for around 75% of all deaths worldwide by 2020. Therefore, this is expected to aid in market growth, as needle is an integral part of chronic disease treatment. For instance, according to Diabetic Atlas by International Diabetes Federation (IDF), 2017, diabetes affected around 425 million people worldwide. Patients suffering from diabetes require daily administration of insulin with continuous glucose monitoring, which in turn is propelling demand for pen needles. Furthermore, the U.S. majorly invest in treatment of diabetes and cancer, annually. For instance, around US$ 377 Billion are invested, which account for 52% of the total diabetes expenditure worldwide, according to the IDF report 2017. Also, according to World Cancer Research Organization, 2014 report, cancer incidence in the U.S. is one of highest at 328 per 100,000, which is expected to propel growth of the needles market in this region.

Key players are focusing on strategic mergers and acquisitions and development of innovative products, in order to enhance their market share. For instance, in September 2017, Becton, Dickinson and Company introduced BD Ultra-Fine micro pen needle for use with different pen injection devices, for people with diabetes, in order to reduce accidentally injection of insulin dose into a muscle and it provides one of shortest length pen needle. Nipro Medical Corporation launched ‘SafeTouch’ safety needle in 2016, which is known to protect the patients from needle stick injuries. Terumo Medical Corporation innovative product K-Pack Surshield launched in 2012 claims to be 20% sharper than its competitor and fits in all types’ syringes.


Some of the key players operating in the global needles market are Becton, Dickinson and Company, Medtronic plc, Hamilton Company, Stryker Corporation, Terumo Corporation, B. Braun Melsungen AG, Boston Scientific Corporation, Nipro Medical Corporation, Novo Nordisk A/s, Thermo Fisher Scientific, and Smiths Medical.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Posted by at No comments:
Labels:

Cell Expansion Market Trends, Growth And Future Outlook By 2026

Cell expansion is the large scale artificial production of daughter cells from a single cell, to support medical research. Rising preference for regenerative medicines offering faster results, and emergence of cell-based therapies with high patient compatibility are expected to fuel the cell expansion market during the forecast period (2017–2025). Regenerative medicine helps the body to form new functional tissue to replace defective or lost ones providing treatment for conditions with inadequate therapies. According to the U.S. Department of Health and Services, in 2016, NIH invested around US$ 1.5 billion in stem cell research projects. Increasing government and private sector expenditure on cell-based research therapies is expected to boost growth of the market for cell expansion in the near future. The number of FDA approvals for clinical trials of stem cell-based treatments is rapidly increasing. According to a report published by Pharmaceutical Research and Manufacturers of America, in 2013, around 69 cell therapies with clinical trials were under review with the FDA. The therapeutic classes represented in these trials include skin diseases, cardiovascular diseases, transplantations, eye conditions, cancer and associated conditions, musculoskeletal disorders, genetic disorders, and digestive disorders.


Increasing incidence of chronic medical conditions is expected to boost growth of the cell expansion market over the forecast period

The increasing cases of chronic and rare medical conditions around the world is another key factor driving demand for cell expansion. For instance, according to World Health Organization (WHO), around 15 million people are projected to suffer from cancer by 2020. The rising prevalence of cancer, is in turn, expected to boost growth of the cell expansion market. Cell-based therapy is also a promising approach for treating chronic kidney disease and is presently the focus of preclinical studies. Recent advancements in regenerative medicine and tissue engineering have created cell-based approaches for the treatment of renal failure. Such treatments include biotechnological approach using implantation of bioengineered kidney constructs, transplanting cells, and bio-artificial renal systems. However, lack of high-tech instrumentation and skilled workforce coupled with the high cost of operations are expected to hamper growth of the cell expansion market.

North America is expected to hold a dominant position in the cell expansion market due to increasing demand for regenerative medicines and rising incidence of chronic diseases

Regional segmentation of the cell expansion market by Coherent Market Insights includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. The cell expansion market in North America is driven by the increasing demand for regenerative medicines that are highly compatible with patients and offer rapid results. For instance, the FDA is increasingly approving treatments involving cells derived from bone or blood marrow, due to its well-established efficacy and safety. Furthermore, increasing incidence of chronic diseases and rising R&D investments for the development of cell-based products are other factors expected to support growth of the cell expansion market. According to a study published in NIH report, around 500,000 people benefit from a transplant each year using regenerative medicine in the U.S. Increasing R&D expenditure by several companies for the development of new therapeutic products and availability of untapped growth opportunities are expected to drive the cell expansion market in Asia Pacific. Biotechnology merger and acquisition (M&A) activities have also experienced a boost in the region. According to investment bank China Renaissance, in 2016, 37 pharmaceutical and biotech M&A deals worth US$ 6.8 billion were closed in China.

Major industry players use merger and acquisitions as their major growth strategy

Key players operating in the cell expansion market include Becton, Dickinson and Company, Beckman Coulter, Inc., Corning, Inc., GE Healthcare, Lonza, Merck KGaA (Sigma-Aldrich Co. LLC), Miltenyi Biotec, Thermo Fisher Scientific, Inc., Terumo BCT, Inc., and Stemcell Technologies, Inc. In July 2016, GE Healthcare acquired Biosafe SA, a Swiss company that manufactures instruments that recover stem cells and help in various other cell processing procedures related to personalized medicine. This acquisition will help GE Healthcare to grow the cells in the sample for appropriate dose sizes.


About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Posted by at No comments:
Labels:

Tuesday, 30 July 2019

Diabetes Monitoring Devices Market Trends, Growth And Future Outlook By 2025


Diabetes, also known as Diabetes Mellitus (DM), is a group of metabolic disorders characterized by high blood sugar levels. The symptoms of high blood sugar include, frequent urination, increased thirst, and increased hunger. Acute complications in diabetes include, diabetic ketoacidosis, hyperosmolar hyperglycemic state, or death. Other severe complications include, cardiovascular disease, stroke, chronic kidney disease, foot ulcers, and damage to the eyes. The disorder is mainly due to the inability of pancreas to produce enough insulin. Moreover, the disease causes due to lack of response of cells of the body to the insulin.


Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1278


As diabetes is a chronic disease, there is no known cure and keeping blood sugar levels as close to normal is one of the very few methods in management of the disease. Blood sugar levels can be monitored and tracked using assistive medical devices known as diabetes monitoring or blood glucose monitoring devices. These devices are available for patients suffering from both type I and type II diabetes. High prevalence of diabetes due to changing lifestyle is increasing demand for diabetes monitoring devices in developed as well as emerging economies, which in turn is propelling growth of the market.


The global Diabetes Monitoring Devices Market was valued at US$ 15,276.1 million in 2016 and is expected to witness a robust CAGR of 8.87% over the forecast period (2017 – 2025).


An extensive patient pool serves as a major driving factor for the diabetes monitoring devices market


Increasing incidence of diabetes across the world is one of the primary factor responsible to drive growth of the global diabetes monitoring devices market. For instance, according to the World Health Organization (WHO), 2014, around 8.5% of adults aged 18 and above accounting for 422 million adults were suffering from diabetes worldwide. Moreover, diabetes was the cause of 1.6 million deaths in 2015 and high blood glucose levels was the cause of another 2.2 million deaths. According to National Diabetes Statistics Report 2017 published by Centers of Disease Control and Prevention (CDC), around 9.4% of American population, which includes all age groups i.e., pediatric, adults and geriatric population accounting for 30.3 million people are suffering from diabetes whereas 33.9% of the rest population is diagnosed with pre-diabetes. The prevalence of diabetes is significant among the emerging economies of Asia. According to a study report published in World Journal of Diabetes 2012, Asian economies contribute to more than 60% of the diabetic population in the world. The massive prevalence of diabetes is thus expected to create a demand for monitoring blood glucose devices, which in turn is expected to foster growth of the global diabetes monitoring devices market.


Advancements in the glucose monitoring devices to boost growth of the global market


Market players are actively investing into research for developing innovative solutions by integrating units to monitor the insulin levels and maintain the blood glucose levels by automatically delivering insulin to parts of the body with the help of continuous glucose monitoring systems. For instance, in September 2017, the U.S. FDA approved first blood sugar monitor that does not require finger pricks and uses a small sensor that can be attached to the upper arm for continuous glucose monitoring. Moreover, in February 2018, Medtronic Plc introduced a next generation continuous glucose monitoring system named iPro 2 Professional to improve diabetes management in 41 economies around the world.




The key players operating the global diabetes monitoring devices market include Bayer Healthcare AG, Medtronic, Dexcom, Sanofi, Abbott Laboratories, MediWise, Arkay, Inc., Cnoga Medical, and Bigfoot Biomedical.


About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702

Posted by at No comments:
Labels:

Immuno-Oncology Drugs Market Trends And Growth By 2025

Immuno-Oncology refers to the use of the body’s natural defences to fight disease. It works by stimulating the immune system instead of fighting the tumors, avoiding disturbance in functionality of healthy cells. It helps the immune system to recognize and target cancer cells. The therapy facilitates long term response against cancer by providing long-lasting memory to the immune system. Immuno-Oncology therapy works against a wide variety of cancer, which include non-small cell lung cancer, acute myeloid leukemia, lymphoma, multiple myeloma, breast cancer, and others. Immuno-oncology uses different types of cell-based immune therapies such as monoclonal antibodies, immune checkpoint inhibitors, cytokine based immunotherapy, cancer vaccines, and other therapies. Depending on the functioning of these therapies they are further classified into subtypes such as radiolabeled antibodies, chemo labeled antibodies, and bispecific monoclonal antibodies. Commercially available immune-oncology therapies include Iplimumab, Nivolumab, Rituximab, Blinatumomab, Proleukin, Gardasil, and Kymriah.


Introduction of novel immune-oncology therapies with lesser side effects is driving growth of the global immune-oncology drugs market

Improved therapeutic outcomes have led to increasing success rates against cancer, owing to in-depth understanding of the disease pathophysiology, functioning of the tumor cells, and effective ways to tackle with the same. Moreover, immuno-oncology therapies have lesser side effects compared to conventional cancer therapies such as chemotherapy, radiation therapy, and others. Immuno-oncology therapy operates through the immune system of the body and does not harm healthy cells as opposed to conventional therapies such as targeted therapy, chemotherapy, and radiation therapy that affect cancerous as well as healthy cells. Novel immune therapies can restore the ability of the immune system to identify and eliminate cancer cells, which is generally suppressed during course of cancer progression. Such immuno-oncology based therapies can be tailored to attack or block particular targets. For instance, Iplimumab, a, human monoclonal antibody, which blocks cytotoxic T-lymphocyte-associated antigen-4 is available. Furthermore, agents focusing on specific immune regulatory checkpoints programmed death-1 (PD-1) and programmed death ligand-1 and 2 (PD-L1) such as Nivolumab, Atezolimumab, and Pembrolizumab are being used for cell lung cancer. Monoclonal antibodies have been further developed into conjugated monoclonal antibodies, which are combined with other agents such as radiolabeled antibodies and chemo labeled antibodies. Cancer vaccines have also been developed such as Sipuleucel-T, Gardasil, and Cervarix. These vaccines either work as preventive vaccines or therapeutic vaccines. Adoptive cell transfer therapies is a new therapy emerging in the immuno-oncology such as CAR-T Cell Therapy under, which Kymriah and Yescarta are available.

The global immuno-oncology drugs market was valued at US$ 43,084.5 million in 2016 and is expected to witness a robust CAGR of 14.9% over the forecast period (2017 – 2025).

Active research and development by leading players as well as small innovative organizations are expected to boost growth of the immune-oncology drugs market

According to the World Health Organization (WHO), cancer was responsible for 8.8 million deaths in 2015. Owing to benefits associated with these therapies, the leading players are actively investing in research and development into this treatment category through various collaborations and individual research studies. For instance, EMD Serono is involved in research and development of immune-oncology drugs and has a few drugs in pipeline such as M7824 (investigational) bifunctional immunotherapy. In 2015, Merck & Co., a leading drug manufacturer and MD Anderson Cancer Center entered into a strategic clinical research collaboration for formers drug Keytruda (Pembrolizumab). Celsee Diagnostics and IncellDx announced an immuno-oncology research agreement in 2017. Bristol-Myers Squibb is developing immuno-oncology approaches for treatment of colorectal cancer, lung cancer, melanoma, liver cancer, lymphoma, multiple myeloma, and others. Amgen, Inc. is actively involved in immune-oncology research and the company launched an immunotherapy collaboration with Kite Pharma to develop and commercialize chimeric antigen receptor (CAR) T cells in 2015.

Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1271

Some major players operating in the immuno-oncology drugs market include Amgen, Inc. AstraZeneca Plc, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co., F. Hoffmann-La Roche AG, Johnson & Johnson, Novartis International AG, AbbVie, Inc., Pfizer Inc., Sanofi S.A., EMD Serono, Inc., Gilead Sciences Inc., Prometheus Therapeutics & Diagnostics, Aduro BioTech, Galena Biopharma, Bavarian Nordic, Celldex Therapeutics, ImmunoCellular Therapeutics, and Incyte.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Posted by at No comments:
Labels:

Monday, 29 July 2019

Prostate Cancer Therapeutics Market Trends And Growth

Prostate cancer is caused by the uncontrolled growth of the cells in the prostate gland. Prostate cancer is the most common cancer in men in the U.S., after skin cancer. According to the American Community Survey, 2016, in U.S. prostate cancer is the second leading cause of death among the cancer deaths in men. Almost all prostate cancers are adenocarcinomas (cancers that begin in cells that make and release mucus and other fluids). Other types of prostate cancer are rare; these include: Sarcomas, small cell carcinomas, neuroendocrine tumors and transitional cell carcinomas. Advanced stage of prostate cancer can cause men to urinate more often or have a weaker flow of urine, but these symptoms can also be caused by benign prostate conditions. In 2017, the American Cancer Society estimated around 161,360 new diagnoses of prostate cancer in the U.S., leading to around 26,730 fatalities. As the cause of the cancer is not known, there is no definite way to prevent prostate cancer. The American Cancer Society (ACS) and the National Comprehensive Cancer Network (NCCN) recommends that all men over age 40 should have an annual rectal examination and that men have an annual prostate-specific antigen (PSA) test beginning at age of 50 years.


Rising implications associated with prostate cancer are expected to affect the prostate cancer therapeutics market

Prostate cancer incidence is strongly related to age, with the highest incidence rates being in older men. According to National Cancer Registry Ireland, 2011, median age at prostate cancer diagnosis in Ireland was 67 years with 38.9% of cases being diagnosed in men and 21.3% in men 75+ years. Median age at death was 80 with 70.3% of deaths occurring in men 75+ years. Moreover, Supportive initiatives undertaken by key players in collaboration with various governments to create more awareness of clinical symptoms about prostate cancer and availability of screening & diagnostic tests such as Prostate-Specific Antigen (PSA) and Digital Rectal Exam (DRE) resulting in early detection are also the factors which expected to boost the prostate cancer therapeutics market.  However, high cost associated with drugs, and poor reimbursement of treatment cost may affect the prostate cancer therapeutics negatively.

Endeavor to introduce highly effective therapies for prostate cancer would support the market growth

Many research organizations and universities are investing in research for the development of therapeutic products for the treatment of such tumors. For instance, some pipeline products which are in phase 2 studies, such as Avelumab (Duke University Medical Center), Metformin (Mansoura University), LY2452473 (Dana-Farber Cancer Institute) are expected to arrive in the market in the near future. Furthermore, many products that are about to face patent expiry during the forecast period will also contribute in the growth of the generic prostate cancer therapeutics market.  Many pharmaceutical companies are also focusing on introducing their respective drugs in different countries to boost the sales of their products. For instance, in December, 2016, Sanofi’s prostate cancer drug name Jevtana (cabazitaxel) for the treatment of metastatic hormone-refractory prostate cancer (mHRPC) was approved by Scottish Medicines Consortium (SMC) for restricted use within NHS Scotland, due to which Scotland has now collaborated with health authorities in Northern Ireland, England and Wales. Thereby, reducing potential disparities in care across the UK for this vulnerable group of patients.

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/1257

Key players operating in the prostate cancer therapeutics market include Johnson & Johnson, Astella, Inc, Sanofi-Aventis, Bayer AG, AstraZeneca Plc, Pfizer Inc., Dendreon Corporation (Sanpower Group Co. Ltd.), Ipsen Group, Tolmar Inc, Endo Pharmaceuticals, AbbVie, Inc.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Posted by at No comments:
Labels:

Carcinoid Syndrome Diarrhea Treatment Market Trends And Growth

Carcinoid syndrome is caused by secretion of certain harmful chemicals by carcinoid tumors. Carcinoid syndrome may occur due to infection or other related diseases, and medical or surgical treatments such as anesthesia, chemotherapy, embolization, and tumor debulking. The key symptoms of the syndrome include flushing of the skin and diarrhea, rapid heartbeat, and bronchoconstriction. If remained undiagnosed, it could lead to several complications such as weight loss, electrolyte imbalance, dehydrations, menopause, irritable bowel disease, and asthma. For instance, in 2009, a study by Journal of Clinical Oncology, showed 4 to 5 out of every 100,000 people are diagnosed with a neuroendocrine tumor and over 100,000 people suffering from neuroendocrine tumor in the U.S., also most individual suffering from carcinoid are asymptomatic until the tumor is fully developed. To overcome the carcinoid crisis, treatment options may considered such as surgery, chemotherapy, targeted radionuclide therapy, radiofrequency ablation, and chemoembolization on the basis of patient-by-patient. Carcinoid syndrome being a rare condition, there are very few if any treatment options available. This in turn, creates a highly lucrative opportunities for market players.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞 𝐎𝐟 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.coherentmarketinsights.com/insight/request-pdf/1216

𝐆𝐥𝐨𝐛𝐚𝐥 𝐂𝐚𝐫𝐜𝐢𝐧𝐨𝐢𝐝 𝐒𝐲𝐧𝐝𝐫𝐨𝐦𝐞 𝐃𝐢𝐚𝐫𝐫𝐡𝐞𝐚 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐓𝐚𝐱𝐨𝐧𝐨𝐦𝐲:

By Treatment Type:
  • Chemotherapy
  • Oral Therapy
  • Somatostatin Analog (SSA) Therapy
By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

𝐍𝐨𝐯𝐞𝐥 𝐠𝐫𝐨𝐮𝐧𝐝-𝐛𝐫𝐞𝐚𝐤𝐢𝐧𝐠 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐭𝐨 𝐩𝐫𝐨𝐯𝐢𝐝𝐞 𝐢𝐦𝐦𝐞𝐧𝐬𝐞 𝐨𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬 𝐟𝐨𝐫 𝐦𝐚𝐫𝐤𝐞𝐭 𝐠𝐫𝐨𝐰𝐭𝐡

In February 2017, Lexicon Pharmaceutical Inc., announced that the U.S. Food and Drug Administration (FDA) approved Xermelo (Telotristat etiprate) as the first and only orally administered therapy for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy (SSA) for adults. Xermelo mainly targets the overproduction of serotonin hormone inside mNET cells and reduces the frequency of carcinoid syndrome diarrhea. Furthermore, in 2017, Ipsen Biopharmaceutical, announced the U.S. Food and Drug Administration (FDA) approval for a supplemental indication of Somatuline Depot (lanreotide) Injection 120 mg for the treatment of carcinoid syndrome, to reduce the frequency of short-acting somatostatin analogue rescue therapy.

Development of first-of-its-kind therapeutic approach to treat carcinoid syndrome diarrhea creates highly lucrative growth opportunities for market players. However, low awareness and certain side effects associated with this therapy are expected to hinder growth of the carcinoid syndrome diarrhea treatment market.

𝐈𝐧𝐜𝐫𝐞𝐚𝐬𝐢𝐧𝐠 𝐩𝐫𝐞𝐯𝐚𝐥𝐞𝐧𝐜𝐞 𝐨𝐟 𝐫𝐚𝐫𝐞 𝐜𝐚𝐫𝐜𝐢𝐧𝐨𝐢𝐝 𝐬𝐲𝐧𝐝𝐫𝐨𝐦𝐞 𝐝𝐢𝐚𝐫𝐫𝐡𝐞𝐚 𝐭𝐨 𝐛𝐨𝐨𝐬𝐭 𝐦𝐚𝐫𝐤𝐞𝐭 𝐠𝐫𝐨𝐰𝐭𝐡

According to the National Organization for Rare Disorders (NORD), 2017, each year, only 27 individuals per million population are estimated to be diagnosed with carcinoid tumors in the U.S., amongst whom, only 10% individuals develop carcinoid syndrome. Moreover, it affects both males and females in equal number. Increasing prevalence of the disease is in turn, increasing demand for carcinoid syndrome diarrhea treatment devices. This in turn is expected to fuel growth of the carcinoid syndrome diarrhea treatment market.

𝐁𝐫𝐨𝐰𝐬𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐅𝐨𝐫 𝐌𝐨𝐫𝐞 𝐈𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 @ https://www.coherentmarketinsights.com/ongoing-insight/carcinoid-syndrome-diarrhea-treatment-market-1216

𝐌𝐚𝐣𝐨𝐫 𝐤𝐞𝐲 𝐩𝐥𝐚𝐲𝐞𝐫𝐬 𝐨𝐩𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐢𝐧 𝐭𝐡𝐞 𝐜𝐚𝐫𝐜𝐢𝐧𝐨𝐢𝐝 𝐬𝐲𝐧𝐝𝐫𝐨𝐦𝐞 𝐝𝐢𝐚𝐫𝐫𝐡𝐞𝐚 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐦𝐚𝐫𝐤𝐞𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞 𝐋𝐞𝐱𝐢𝐜𝐨𝐧 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬, 𝐈𝐧𝐜., 𝐍𝐨𝐯𝐚𝐫𝐭𝐢𝐬 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐀𝐆 (𝐒𝐚𝐧𝐝𝐨𝐳), 𝐏𝐡𝐚𝐫𝐦𝐚𝐬𝐜𝐢𝐞𝐧𝐜𝐞 𝐈𝐧𝐜., 𝐎𝐦𝐞𝐠𝐚 𝐋𝐚𝐛𝐨𝐫𝐚𝐭𝐨𝐫𝐢𝐞𝐬 𝐋𝐭𝐝., 𝐓𝐞𝐯𝐚 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐢𝐞𝐬 𝐋𝐭𝐝., 𝐌𝐲𝐥𝐚𝐧 𝐍.𝐕., 𝐈𝐩𝐬𝐞𝐧 𝐁𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬, 𝐈𝐧𝐜., 𝐒𝐢𝐫𝐭𝐞𝐱 𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐋𝐢𝐦𝐢𝐭𝐞𝐝, 𝐚𝐧𝐝 𝐁𝐓𝐆 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐋𝐭𝐝.

𝐀𝐛𝐨𝐮𝐭 𝐂𝐨𝐡𝐞𝐫𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐬

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
𝐄𝐦𝐚𝐢𝐥: sales@coherentmarketinsights.com
Posted by at No comments:
Labels:

Friday, 26 July 2019

Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market - Key Companies Profile, Supply and Growth Factors

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease and motor neuron disease (MND), is a neurodegenerative disease, affecting nerve cells in the brain and spinal cord that controls voluntary muscles. The disease is progressive in nature, meaning it gets worse over time.

According to a study published in Centers for Disease Control and Prevention, in 2016, around 14,713 people were diagnosed with ALS in the U.S. and prevalence rate of ALS was 4.7 cases per 100,000 people in 2012. The prevalence rate increased to 5.0 cases per 100,000 people and around 15,908 people were diagnosed with ALS in 2013, according to the same study. The increasing prevalence of ALS is in turn, expected to support growth of the amyotrophic lateral sclerosis (ALS) treatment market in the near future.


Approval of novel innovative drugs is expected to boost growth in amyotrophic lateral sclerosis treatment market

In May 2017, The U.S. Food and Drug Administration (FDA) approved Radicava (edaravone), an innovative drug used in the treatment of amyotrophic lateral sclerosis (ALS). This was the first drug to be approved after over 20 years since the last FDA-approved drug for ALS. The approval of this drug would provide an additional option for patients suffering from this deadly disease. Increasing incidence of ALS is expected to increase the adoption rate of this drug, in turn, boosting market growth. The drug has already been approved in Japan and South Korea in 2015.

North America is expected to hold a dominant position in the market, increasing focus of manufacturers on novel drug development for ALS

North America is expected to hold a dominant position in the amyotrophic lateral sclerosis treatment market, as major companies present in the region are focusing on collaborations for product development. For instance, in January 2018 Sangamo Therapeutics, Inc. and Pfizer Inc. collaborated for the development of a potential gene therapy using zinc finger protein transcription factors (ZFP-TFs) for the treatment of ALS. Companies based in emerging economies of Asia Pacific are focusing on developing novel drugs for treatment of ALS. For instant major companies such as Mitsubishi Tanabe Pharma Corporation and Takeda Pharmaceutical Company Ltd are developing drugs for treatment of ALS.

Major players operating in the global amyotrophic lateral sclerosis treatment market include Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Company Ltd., Sanofi S.A., and Mylan Pharmaceuticals Inc.



Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Taxonomy

The global amyotrophic lateral sclerosis treatment market is segmented on the basis of drug type and distribution channel.
On the basis of drug type, the global amyotrophic lateral sclerosis treatment market is segmented into:
  • Riluzole
  • Edaravone (Radicava)
On the basis of distribution channel, the global amyotrophic lateral sclerosis treatment market is segmented into:
  • Hospital Pharmacies
  • Retail & Online Pharmacies
About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Posted by at No comments:
Labels:

Thursday, 25 July 2019

Urinary Catheters Market Forecast to 2026 with Key Companies Profile, Supply and Growth Factors

Urinary catheter is a tube used to collect urine from the bladder. The catheters are mostly recommended by the healthcare providers for people suffering from bladder disorders such as urinary incontinence and urinary retention. The catheters are usually made of latex, silicone, and polyurethane. Foley catheter comprises a balloon for holding the tube in the bladder for long term, whereas intermittent catheters provides short term catheterization. The urinary catheters are inserted into the urethra guiding through the bladder to drain out urine providing convenience to patients post-surgery. External catheters are advanced catheters preventing catheter associated urinary tract infections (CAUTI). Urinary catheters are also used during long surgical procedures for urine drainage for patients with other medical conditions such as spina bifida, multiple sclerosis and spinal injury, as the patients with neurological disease are at a risk for neurogenic lower urinary tract dysfunction known as neurogenic bladder.


Rising prevalence of benign prostate hyperplasia in adults is expected to drive the growth of global urinary catheters market

The urinary catheters market is expected to grow drastically due to rising occurrence of target diseases such as benign prostate hyperplasia (BPH), urinary incontinence, urinary retention, bladder obstruction, and bladder cancers. According to the World Health Organization (WHO) estimates, 2015, over 200 million people are suffering from bladder control problems due to different diseases that essentially require urinary catheterization in 2015. According to the  National Association for Continence, one third of the men and women between the age group of around 55-65 years suffer from bladder control problem at some point in their adult life. Neurological disorders leading to bladder dysfunction also require catheters for urine drainage. The factors such as increasing genital surgeries, availability of improved catheters, and favorable reimbursement policies is expected to boost the market growth.

The urinary catheters market is expected to gain a significant traction over the forecast period with the launch of innovative catheters to minimize the rates of catheter associated infections. According to the study by Antimicrobial Resistance and Infection Control, 2014, catheter-acquired urinary infection is the source for about 20% health-care acquired infections in acute care facilities and over 50% in long term care facilities. In 2016, CompactCath launched smaller and discreet intermittent catheter aimed to address infection related complications and to improve self-catheterization experience.

Increasing number of prostate surgeries is expected to dominate the urinary catheters market in North America

Regional segmentation of the urinary catheters market by Coherent Market Insights comprises North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa. North America is expected to dominate the global market, owing to the rising cases of urinary continence and prostate surgeries. According to the American Academy of Family Physicians (AAFP) estimates in 2013, urinary incontinence affected approximately 20 million American women and 6 million American men with more than 250,000 surgical procedures carried out for benign prostatic hyperplasia (BPH). According to the Urology Care Foundation estimates in 2015, around 150,000 men in the U.S. undergo transurethral resection surgery of the prostate annually, thus increasing the demand for urinary catheters. In 2017, a national performance improvement program named Health Care-Associated Infections/Catheter-Associated Urinary Tract Infection was designed by the Agency for Healthcare Research and Quality Safety Program for Long-term Care to promote implementation of a CAUTI prevention program through state-based or regional collaborative in more than 500 nursing homes across the U.S.


Development of innovative products expanding patient choice is expected to rise the demand for urinary catheters market

Key players operating the urinary catheters market include Hollister Inc., Boston Scientific Corporation, Teleflex Inc., Coloplast, Cook Medical, B Braun Melsungen AG, and Medtronic. In 2016, Coloplast launched the new soft catheter SpeediCath Flex for men, which is designed for easy and hygienic insertion, making catheterization easy. Also, in 2015, Hollister Incorporated launched two new hydrophilic intermittent catheters, the VaPro Plus touch free and Apogee HC hydrophilic intermittent catheter. These catheters provides more options for healthcare professionals and the patients as they are easy-to-carry and store.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Posted by at No comments:
Labels:

Antibiotic Bone Cement and Casting Materials Market Forecast to 2026 with Key Companies Profile, Supply and Growth Factors

Bone cement is a material used for the fixation of joint implants to the bone. Chemical bone cement is Plexiglas, which is a polymer-based material comprising poly-methyl-methacrylate (PMMA) or co-polymers. Infection during orthopedic surgery is a major concern, which makes the use of antibiotic bone cements essential. Casting materials are used for supporting broken or injured bone. These materials act as a supportive wrap or bandage around the broken bone. Casting materials are available in various shapes and sizes, however, the most common type of casting material used in antibiotic bone cement are plasters and fiberglass. Increasing incidents of falls, road-accidents, and sports injuries is expected to foster growth of antibiotic bone cement and casting materials market.


Increasing incidence of fatal falls is expected to boost growth of the bone cement and casting materials market over the forecast period

According to World Health Organization (WHO) 2017, falls are the second leading cause of accidental or unintentional injury deaths, worldwide. Each year an estimated 646,000 individuals die from falls, globally of which over 80% are in low and middle-income countries. Adults older than 65 years of age, are reported to be highest in number in terms of fatal falls and chances of hip fracture, knee factures are very high in this age group. Factures in knee and hip are caused by trauma, fall from height, or vehicle collision. According to World Health Organization (WHO) 2017, yearly around 1.25 million people die and 20–50 million people experience severe injury and fractures due to road accidents. Rising number of road accidents is thus expected to boost growth of the antibiotic bone cement and casting materials market over the forecast. Sports injuries are also one of the major causes of fractures. Increasing sports and outdoor activity trend and low use of protective equipment during sports, leads to severe sports injuries in joints and this is expected to fuel the antibiotic bone cement and casting material market growth in the near future. According to the National High School Sports Related Injury Surveillance System in 2012, 51,733 sports injury cases accounted for fractures encountered during high school sports. High cost of joint replacement surgeries is a factor expected to restrain antibiotic bone cement and casting materials market growth.

Increasing number of fractures in Western Pacific and South East Asia is expected to aid in growth of the bone cement and casting materials market in Asia Pacific in the near future

On the basis of region, antibiotic bone cement and casting materials market by Coherent Market Insights is segmented in to North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. Western Pacific and South East Asia are expected to be lucrative markets owing to rising prevalence of fatal falls and factures. According to WHO 2017, Western Pacific and south East Asia accounted for 60% of deaths and injuries due to fatal falls. Africa market is also expected to witness a robust growth owing to increasing incidents of accidents. According to WHO Global Status Report on Road Safety 2015, the incidents of accidents in low- and middle-income countries are more, and the accident rate in Africa is highest among all the other regions.

Development of new materials is expected to aid in growth of the market

A team from the University of Limerick in 2017 developed a new type of cement, which reduces the time needed for orthopedic operations and helps broken bones to heal and conjoin more quickly. The cement mixes together with a mineral called hydroxyapatite, which is found naturally in bones and teeth. The recently approved bone cement has been used successfully in 4,000 operations and thus holds a strong competition for market players.

To Get Instant Access, Purchase Report Here @ https://www.coherentmarketinsights.com/insight/buy-now/1195

Key players in bone cement and casting materials market are Smith & Nephew plc, Zimmer Biomet Holdings, Exactech, BSN medical GmbH, 3M Health Care Ltd, Stryker Corporation, Orthofix International, and DePuy Orthopaedics.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Posted by at No comments:
Labels:

Urinary Tract Infection Treatment Market Forecast to 2026 with Key Companies Profile, Supply and Growth Factors

Urinary Tract Infection (UTI) is caused when bacteria enters the urethra and infects the urinary bladder, causing severe health issues. UTI infections are common health problems in females than in males with biologic factors accounting as the major cause. Antibiotics are usually the first line of treatment prescribed by doctors for urinary tract infections. According to the site of manifestation by the microbe, infections are classified as cystitis (bladder), urethritis (urethra), prostatitis (prostate) or pyelonephritis (kidney). Painful and increased frequency of urination, excessive and involuntary passing of urine at night are the common symptoms associated with UTI. Hospitalized patients using urinary catheters are at a higher risk for developing UTI.


Increasing prevalence of recurring urinary infections is expected to boost growth of the urinary tract infection treatment market

Rise in chronic kidney diseases and increasing use of urinary catheterization is leading to development of urinary infections and this is expected to be major growth drivers for urinary tract infection market. According to the Centers of Disease Control and Prevention, 2016, UTIs are the most common bacterial infections globally, affecting 150 million people every year. Furthermore, about 10 in 25 women and 3 in 25 men are estimated to have symptoms of at least one UTI during their lifetime. According to the study by Sultan Qaboos University Medical Journal, 2013, around 50–60% of women report at least one UTI in their lifetime, and one in three will have at least one symptomatic UTI necessitating antibiotic treatment by age 24. Also, patients with diabetes have a higher frequency of UTIs, due to the presence of long-term complications of diabetes such as neuropathy. According to the American Diabetes Association, in 2017, 9.4% of the people diagnosed with type 2 diabetes had a UTI compared to only 5.7% of people without diabetes.

Approval of combination products for improving indications of existing drugs and to combat multi-drug resistant bacteria are some key factors positively affecting market growth. For instance, in 2015, FDA approved Avycaz (ceftazidime and avibactam) for complicated abdominal and urinary tract infections in combination with metronidazole that has limited or no alternative treatment options.

To Get Instant Access, Purchase Report Here @ https://www.coherentmarketinsights.com/insight/buy-now/1178

Strategic collaborations is the strategy adopted by key players in the market to enhance its presence and for new drug development

Strategy of leading players is to achieve growth through mergers & acquisitions and collaborations. In 2016, GlaxoSmithKline and Fimbrion Therapeutics, Inc., entered into a collaboration, which is focused on preclinical development of mannose-containing small molecule compounds called mannosides for the treatment and prevention of urinary tract infections.

Key players operating in the urinary tract infection treatment market include Cipla Ltd., Johnson & Johnson, Bayer AG, Pfizer Inc., GlaxoSmithKline, Boehringer Ingelheim, F. Hoffmann-La Roche Ltd., Novartis AG AstraZeneca Plc, and Roche Ltd.


About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Posted by at No comments:
Labels:
Subscribe to: Comments (Atom)